Global Dementia and Movement Disorder Treatment Market 2025-2029

Dementia And Movement Disorder Treatment Market 2025-2029

The dementia and movement disorder treatment market is forecasted to grow by USD 14429.5 mn during 2024-2029, accelerating at a CAGR of 9% during the forecast period. The report on the dementia and movement disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, rising prevalence of target diseases, and emergence of strategies to increase public awareness.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's dementia and movement disorder treatment market is segmented as below:

By Application

• Movement disorders
• Progressive dementia
• Progressive dementia with neurological abnormality (PDNA)

By Drug Class

• MAO inhibitors
• Acetylcholinesterase inhibitors
• Glutamate inhibitors
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the emergence of biomarkers as one of the prime reasons driving the dementia and movement disorder treatment market growth during the next few years. Also, growth of gene therapy to reverse cognitive decline associated with alzheimer disease and advances in biomedical science will lead to sizable demand in the market.

The report on the dementia and movement disorder treatment market covers the following areas:

• Dementia And Movement Disorder Treatment Market sizing
• Dementia And Movement Disorder Treatment Market forecast
• Dementia And Movement Disorder Treatment Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dementia and movement disorder treatment market vendors that include AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson Services Inc., Kirin Holdings Co. Ltd., Lannett Co Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA. Also, the dementia and movement disorder treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.